Details for Patent: 8,642,573

Which drugs does patent 8,642,573 protect, and when does it expire?

Patent 8,642,573 protects XIFAXAN and is included in one NDA.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: 8,642,573

Title:	Methods of treating hepatic encephalopathy
Abstract:	The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.
Inventor(s):	Forbes; William (Raleigh, NC), Merchant; Kunal (Durham, NC), Bortey; Enoch (Chapel Hill, NC), Shaw; Audrey (Durham, NC)
Assignee:	Salix Pharmaceuticals, Ltd (Raleigh, NC)
Application Number:	13/737,535
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,642,573
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,642,573

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	XIFAXAN	rifaximin	TABLET;ORAL	021361-002	Mar 24, 2010		RX	Yes	Yes						REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE

International Family Members for US Patent 8,642,573

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009298389
Australia	2010260089
Australia	2010271070